Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: Results from the EDEMA clinical trials

Allergy and Asthma Proceedings

Volumn 32, Issue 4, 2011, Pages 319-324

  Banta, Erin ^a   Horn, Patrick ^b   Craig, Timothy J ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b Dyax Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECALLANTIDE; PLACEBO;

ADOLESCENT; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANGIOEDEMAS, HEREDITARY; CHILD; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; PEPTIDES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960736819     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2011.32.3440     Document Type: Article

References (21)

1. Bork K, Barnstedt SE, Koch P, and Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 356:213-217, 2000.
2. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med 359:1027-1036, 2008.
3. Agostoni A, Aygoren-Pursun E, Binkley KE, et al. Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 114(suppl):S51-S131, 2004.
4. Cugno M, Zanichelli A, Foieni F, et al. C1-inhibitor deficiency and angioedema: Molecular mechanisms and clinical progress. Trends Mol Med 15:69-78, 2009.
5. Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: Consensus document. Clin Exp Immunol 139:379-394, 2005.
6. Bork K, Meng G, Staubach P, and Hardt J. Hereditary angioedema: New findings concerning symptoms, affected organs, and course. Am J Med 119:267-274, 2006.
7. Farkas H, Harmat G, Fust G, et al. Clinical management of hereditary angio-oedema in children. Pediatr Allergy Immunol 13:153-161, 2002.
8. Bernstein JA. Hereditary angioedema: A current state-of-the-art review, VIII: Current status of emerging therapies. Ann Allergy Asthma Immunol 100(suppl 2):S41-S46, 2008.
9. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 6:24, 2010.
10. Pharming Press Release July 2009. Pharming confirms positive results from final analysis of Rhucin(R) studies. Available online at www.tradingmarkets. com/.site/news/Stock%20News/2399906/; last accessed April 29, 2010.
11. Craig T, Wassermann RL, Levy R, et al. C1 esterase inhibitor (C1-INH) - Standard of care for the treatment of acute attacks in hereditary angioedema (HAE): Initial results of an ongoing, prospective, open label study in North America (I.M.P.A.C.T. 2). J Allergy Clin Immunol 121(suppl 1):S98-S99, 2008.
12. Bernstein J, Ritchie B, Levy R, et al. Hereditary angioedema: Validation of the end point time to onset of relief by correlation with symptom intensity. Allergy Asthma Proc 105:430-436, 2010.
13. Bork K, Meng G, Staubach P, and Hardt J. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 45:1774-1784, 2005.
14. Bernstein JA, and Qazi M. Ecallantide: Its pharmacology, pharmacokinetics, clinical efficacy and tolerability. Expert Rev Clin Immunol 6:29-39, 2010.
15. Zuraw B, Yasothan U, and Kirkpatrick P. Ecallantide. Nat Rev Drug Discov 9:189-190, 2010.
16. Levy RJ, Lumry WR, McNeil DL, et al. EDEMA4: A phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 104:523-529, 2010.
17. Cicardi M, Levy R, McNeil D, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 363:523-531, 2010.
18. Vernon MK, Rentz AM, Wyrwich KW, et al. Psychometric validation of two patient-reported outcome measures to assess symptom severity and changes in symptoms in hereditary angioedema. Qual Life Res 18:929-939, 2009.
19. Riedl M, Campion M, Horn PT, and Pullman WE. Response Time for ecallantide treatment of acute hereditary angioedema attacks. Ann Allergy Asthma Immunol 32:36-42 (Epub ahead of print October 26, 2010; Ann Allergy Asthma Immunol doi: 10.1016/j.anai.2010.09.005.)
20. Prematta MJ, Kemp JG, Gibbs JG, et al. Frequency, timing, and type of prodromal symptoms associated with hereditary angioedema attacks. Allergy Asthma Proc 30:506-511, 2009.
21. Kemp JG, and Craig TJ. Variability of prodromal signs and symptoms associated with hereditary angioedema attacks: A literature review. Allergy Asthma Proc 30:493-499, 2009.